Eli Lilly and Company (SWX:LLY)

Market Cap	708.70B +5.2%
Revenue (ttm)	51.68B +44.7%
Net Income	16.37B +94.9%
EPS	18.20 +96.0%
Shares Out	n/a
PE Ratio	43.30
Forward PE	29.51
Dividend	4.99 (0.63%)
Ex-Dividend Date	Feb 13, 2026

Volume	n/a
Average Volume	4
Open	n/a
Previous Close	790.00
Day's Range	n/a
52-Week Range	537.19 - 900.00
Beta	0.33
RSI	41.27
Earnings Date	Feb 4, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 50,000
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: LLY

Financial Performance

In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.

Financial numbers in USD